NEW YORK, April 18 /PRNewswire-FirstCall/ -- Rik J. Deitsch, Chairman and Chief Executive Officer of Nutra Pharma Corporation (BULLETIN BOARD: NPHC) (http://www.nutrapharma.com/) will be updating the investment community through his personal profile on MyWallst.net available at http://www.wallst.net/. The dynamic profile will include exclusive interviews with Rik J. Deitsch, company blogs on which investors can comment, his personal stock watchlist, photos of company products and links to recent press.
Visit Rik J. Deitsch's profile on My.wallst.net at http://my.wallst.net/profile.php?ID=20002.
Stay updated about Nutra Pharma Corporation, ask Rik a question or post a comment on his personal page. Join Nutra Pharma's message board to discuss company activity with other interested parties, "invest" in OTCBB: NPHC through the Rookie Challenge and join his financial social network today.
About WallSt.net:
http://www.wallst.net/ is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com/). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://my.wallst.net/, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com/), a provider of compliance solutions to publicly traded companies. We have received ten thousand dollars from Nutra Pharma Corporation for media and advertising services. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com/), a business and finance podcast Web site.
About Nutra Pharma:
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ('MS'). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
Contact: Nutra Pharma Corporation
877-895-5647
